Prostate smooth muscle tone and hyperplastic growth are involved in the pathophysiology and treatment of male lower urinary tract symptoms (LUTS). Available drugs are characterized by limited efficacy. Patients' adherence is particularly low to combination therapies of 5α-reductase inhibitors and α 1 -adrenoceptor antagonists, which are supposed to target contraction and growth simultaneously. Consequently, molecular etiology of benign prostatic hyperplasia (BPH) and new compounds interfering with smooth muscle contraction or growth in the prostate are of high interest. Here, we studied effects of p21-activated kinase (PAK) inhibitors (FRAX486, IPA3) in hyperplastic human prostate tissues, and in stromal cells (WPMY-1). In hyperplastic prostate tissues, PAK1, -2, -4, and -6 may be constitutively expressed in catecholaminergic neurons, while PAK1 was detected in smooth muscle and WPMY-1 cells. Neurogenic contractions of prostate strips by electric field stimulation were significantly inhibited by high concentrations of FRAX486 (30 μM) or IPA3 (300 μM), while noradrenaline-and phenylephrine-induced contractions were not affected. FRAX486 (30 μM) inhibited endothelin-1-and -2-induced contractions. In WPMY-1 cells, FRAX486 or IPA3 (24 h) induced concentration-dependent (1-10 μM) degeneration of actin filaments. This was paralleled by attenuation of proliferation rate, being observed from 1 to 10 μM FRAX486 or IPA3. Cytotoxicity of FRAX486 and IPA3 in WPMY-1 cells was time-and concentration-dependent. Stimulation of WPMY-1 cells with endothelin-1 or dihydrotestosterone, but not noradrenaline induced PAK phosphorylation, indicating PAK activation by endothelin-1. Thus, PAK inhibitors may inhibit neurogenic and endothelin-induced smooth muscle contractions in the hyperplastic human prostate, and growth of stromal cells. Targeting prostate smooth muscle contraction and stromal growth at once by a single compound is principally possible, at least under experimental conditions.
Introduction
Patients with benign prostatic hyperplasia (BPH) are often characterized by voiding symptoms, caused by bladder outlet obstruction (BOO) due to abnormal prostate smooth muscle tone and prostate enlargement [1] [2] [3] . Besides other receptors, smooth muscle contraction in the prostate is induced by activation of α 1 -adrenoceptors, while hyperplastic growth is triggered by dihydrotestosteron [2, 3] . Consequently, α 1 -blockers or other medications are routinely applied for immediate improvement of symptom scores or urinary flow by relaxation of prostate smooth muscle, while prostate size may be reduced by 5α-reductase inhibitors to prevent progression, complications, and operation [3] . However, medical therapy is still hampered by insufficient efficacy and low patients' adherence to medications [2, 4] . Combination therapies are required to reduce prostate smooth muscle tone and prostate size at once, but are associated with high discontinuation rates [2] [3] [4] .
Limitations of α 1 -blockers may be explained by contributions of non-adrenergic mediators, which may induce prostate smooth muscle contraction even in the presence of α 1 -blockers [2] . Such non-adrenergic mediators, which increase prostate smooth muscle tone in parallel to α 1 -adrenoceptors, include endothelins and thromboxane A2 [2] . In addition, prostate enlargement may contribute to BOO besides contraction, and despite application of α 1 -blockers, as α 1 -blockers do not affect prostate size [3] . Thus, an ideal medication for treatment of voiding symptoms would address adrenergic and non-adrenergic smooth muscle contraction, plus prostate growth at once. Nowadays, a possible context between smooth muscle contraction and growth in the hyperplastic prostate has been assumed, but underlying molecular mechanisms are poorly understood [2, 5] .
Recently, it became clear that previous models being used for more than one decade are insufficient to explain contraction of prostate smooth muscle [2] . Several studies uncovered the role of intracellular effectors, which are involved in control of prostate smooth muscle contraction besides Ca 2+ -, protein kinase C-, or Rho kinase-dependent pathways [2, [6] [7] [8] . Thereby, the monomeric GTPase Rac was identified as a critical mediator of smooth muscle contraction and stromal growth in the prostate [8] . Rac may act together with p21-activated kinases (PAKs) in different cell types [9, 10] . Although Rac signalling in the prostate turned out to be PAK-independent, this suggested for the first time a possible role of PAKs for smooth muscle contraction and growth in the prostate [8] . Nevertheless, effects of PAK inhibitors in the hyperplastic prostate have at present not been examined to the best of our knowledge.
PAKs are a group of serine/threonine kinases, being involved in a broad range of cellular functions, including regulation of cytoskeleton organization, smooth muscle contraction, neuronal function, or cell cycle [10] [11] [12] . PAKs may promote smooth muscle contraction in the airways, gastrointestinal tract, and cardiovascular system [13] [14] [15] [16] [17] [18] [19] [20] [21] . Besides this role for smooth muscle tone, PAKs may be involved in the control of cell cycle in airway and vascular smooth muscle cells [22] [23] [24] [25] . In the prostate, PAK has been regarded in oncological context, but to the best of our knowledge not in the non-malignant organ [26] [27] [28] [29] [30] . However, based on its dual role for smooth muscle contraction and cell cycle of smooth muscle cells outside the lower urinary tract, it appears tempting to assume similar PAK functions in the prostate. Due to the contributions of smooth muscle contraction and growth in the prostate to voiding symptoms in millions of patients, understanding the molecular control of both processes and identification of their mediators is in fact attractive. Together, this prompted us to examine PAK expression and effects of PAK inhibitors in the hyperplastic human prostate, and in prostate stromal cells.
Methods

Human prostate tissues
Human prostate tissues were obtained from patients undergoing radical prostatectomy for prostate cancer, but without previous transurethral resection of the prostate (TURP). The research was carried out in accordance with the Declaration of Helsinki of the World Medical Association, and has been approved by the ethics committee of the Ludwig-Maximilians University, Munich, Germany (approval number 158-15). Informed written consent was obtained from the participants; data were analysed anonymously. Tissues were taken from the periurethral zone, while most prostate tumors are located to the peripheral zone [31, 32] . Tissue samples did not exhibit histological signs of neoplasia, cancer, or inflammation. BPH is present in ca. 80% of patients with prostate cancer [33, 34] . Samples were taken immediately after prostatectomy, following macroscopical examination by a pathologist. Organ bath studies were performed immediately after sampling, while samples for molecular analyses were shock frozen in liquid nitrogen and stored at -80°C.
Real time polymerase chain reaction (PCR)
RNA from frozen prostate tissues was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany). For isolation, 30 mg of tissue was homogenized using the FastPrep 1 -24 system with matrix A (MP Biomedicals, Illkirch, France). RNA concentrations were measured spectrophotometrically. Reverse transcription to cDNA was performed with 1 μg of isolated RNA using the Reverse Transcription System (Promega, Madison, WI, USA). Real time-(RT-) PCR for PAK isoforms, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed with a Roche Light Cycler (Roche, Basel, Switzerland) using primers provided by Qiagen (Hilden, Germany) as ready-to-use mixes, based on the RefSeq Accession numbers NM_001128620 for PAK1, NM_002577 for PAK2, NM_001128166 for PAK3, NM_001014831 for PAK4, NM_020341 for PAK5, NM_001128628 for PAK6, and NM_002046 for GAPDH. PCR reactions were performed in a volume of 25 μl containing 5 μl LightCycler 1 FastStart DNA Master Plus SYBR Green I (Roche, Basel, Switzerland), 1 μl template, 1 μl primer, and 18 μl water.
Denaturation was performed for 10 min at 95°C, and amplification with 45 cycles of 15 sec at 95°C followed by 60 sec at 60°C. The specificity of primers and amplification was demonstrated by subsequent analysis of melting points, which revealed single peaks for each target. Results were expressed based on the number of cycles (Ct), at which the fluorescence signal exceeded a defined treshold.
Western blot analysis
Frozen prostate tissues were homogenized in a buffer containing 25 mM Tris/HCl, 10 μM phenylmethanesulfonyl fluoride, 1 mM benzamidine, and 10 μg/ml leupeptine hemisulfate, using the FastPrep 1 -24 system with matrix A (MP Biomedicals, Illkirch, France). After centrifugation (20,000 g, 4 min), supernatants were assayed for protein concentration using the Dc-Assay kit (Biorad, Munich, Germany) and boiled for 10 min with sodium dodecyl sulfate (SDS) sample buffer (Roth, Karlsruhe, Germany Western blot analysis, cells were lyzed using radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO, USA), and removed from flasks after 15 min of incubation on ice. Cell debris was removed by centrifugation (10,000 g, 10 min, 4°C), and different aliquots of supernatants were either subjected to protein determination, or boiled with SDS sample buffer.
Phalloidin staining
For fluorescence staining with phalloidin, cells were grown on Lab-Tek Chamber slides (Thermo Fisher, Waltham, MA, USA) with inhibitors, or solvent. Staining was performed using 100 μM FITC-labeled phalloidin (Sigma-Aldrich, Munich, Germany), according to the manufacturer's instruction. Labeled cells were analyzed using a laser scanning microscope (Leica SP2, Wetzlar, Germany).
Cytotoxicity assay
Cytotoxicity of PAK inhibitors was assessed using the Cell Counting Kit-8 (CCK-8) (SigmaAldrich, St. Louis, MO, USA). Cells were grown in 96-well plates (20,000 cells/well) for 24 h, before FRAX486, IPA3, or DMSO were added in indicated concentrations (1, 5, 10 μM). Subsequently, cells were grown for different periods (24, 48, 72 h ). Separate controls were performed for each period. At the end of this period, 10 μl of [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) from CCK-8 was added, and absorbance in each well was measured at 450 nm after incubation for 2 h at 37°C.
Cell proliferation assay
WPMY-1 cells were plated with a density of 50,000/well on a 16-well chambered coverslip (Thermo Scientific, Waltham, MA, USA). After 24 h, cells were treated with FRAX486 (1, 5, 10 μM), IPA3 (1, 5, 10 μM), or DMSO. After further 24 h, the medium was changed to a 10 mM 5-ethynyl-2'-deoxyuridine (EdU) solution in FCS-free medium containing inhibitors or solvent. 20 h later, cells were fixed with 3.7% formaldehyde. EdU incorporation was determined using the "EdU-Click 555" cell proliferation assay (Baseclick, Tutzing, Germany) according to the manufacturer`s instructions. In this assay, incorporation of EdU into DNA is assessed by detection with fluorescing 5-carboxytetramethylrhodamine (5-TAMRA). Counterstaining of all nuclei was performed with DAPI. Cells were analyzed by fluorescence microscopy (excitation: 546 nm; emission: 479 nm).
Phosphorylation assessments
Activation of PAK1-3 involves autophosphorylation at threonine 402 or corresponding sites (threonine 423), which may be assessed using site-and phospho-specific antibodies [8, [35] [36] [37] . For assessments of agonist-induced PAK phosphorylation, WPMY-1 cells were grown in T75 flasks. After 48 h, medium was changed to FCS-free medium. After 24 h, serum-starved cells were stimulated with endothelin-1 (3 μM) or endothelin-2 (3 μM) for 10 or 20 min, with noradrenaline (100 μM) for 5 or 10 min, or with dihydrotestosterone (100 μM) for 8 or 48 h. Controls without stimulation but identical total exposure time were included in each single experiment and for each agonist. Subsequently, cells were lysed using lysis buffer, and removed from flasks after 15 min of incubation on ice. Cell debris was removed by centrifugation (10,000 g, 10 min, 4°C), and aliquots of supernatants were directly subjected to protein determination. These samples were subjected to Western blot analysis for phospho-PAK, PAK1, or β-actin, which was performed using rabbit anti p-α/β/γPAK (Thr402) (sc-135684), mouse anti αPAK (sc-166887), or mouse anti β-actin antibody (sc-47778) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). On each Western blot, samples from the same experiment were compared (agonist vs. controls). Intensities of resulting bands were quantified densitometrically using "Image J" (NIH, Bethesda, Maryland, USA). For semiquantitative calculation, samples without agonists (controls) were set to 100%, and samples with agonists were expressed as % of controls. This normalization is inevitable due to high variation of control values obtained by densitometric quantification (providing "arbitrary units"). These variations mostly result from detection conditions (slight differences of incubation periods, exposure times), and from different adjustments during digitization of blots (required due to varying background or PAK content). These variations of control values may practically not be avoided; therefore, normalization of controls was required. However, groups containg normalized controls should not be subjected to t-tests, so that statistical tests were not applied to quantifications of phosphorylation experiments.
Drugs and nomenclature
pyrimidin-7(8H)-one (FRAX486) and 1,1'-dithiodi-2-naphthtol (IPA3) are structurally unrelated inhibitors of PAKs. Stock solutions (10 mM) were prepared with DMSO, and kept at -20°C until use. Phenylephrine ((R)-3-[-1-hydroxy-2-(methylamino)ethyl]phenol) is a selective agonist for α 1 -adrenoceptors. Aqueous stock solutions of phenylephrine and norepinephrine (10 mM) were freshly prepared before each experiment. FRAX486 and IPA3 were obtained from Tocris (Bristol, UK), phenylephrine and norepinephrine were obtained from Sigma (Munich, Germany).
Statistical analysis
Data are presented as means ± standard error of the mean (SEM) with the indicated number (n) of experiments. Two-tailed student t test was used for paired or unpaired observations. P values <0.05 were considered statistically significant.
Results
Detection of PAK isoforms in prostate tissues and WPMY-1 cells
The PAK family comprises PAK1 (syn. α-PAK), PAK2 (syn. γ-PAK), PAK3 (syn. β-PAK), PAK4, PAK5 (syn. PAK7), and PAK 6 (syn. PAK5) [10, 11] . We detected mRNA and protein of different isoforms in periurethral tissues from hyperplastic human prostates, and in cultured WPMY-1 cells. Results from all analyses including RT-PCR, Western blot, and immunofluorescence staining are summarized in Table 1 . In tissues and cells, mRNA for all PAK isoforms was detectable ( Fig 1A, Table 1 ). Western blot analyses were performed using isoform-specific PAK antibodies, and repeated using two different antibodies for each isoform. For evaluation, only bands with sizes matching the corresponding molecular weight of the isoform, or regions covering these sizes were considered. Diverging and additional bands occurred with some antibodies, but were not regarded for conclusions (S1 Fig) .
In Western blot analysis of prostate tissues, the best detectable isoform was PAK1 (Fig 1B) . Bands matching the expected molecular weight of PAK1 were detected using two different antibodies, and in most samples being included to this analysis (Fig 1B) . Despite detection in nearly all samples, varying intensity of bands suggested variations of PAK1 content between different patients (Fig 1B) . Variation was confirmed by both applied antibodies (Fig 1B) . PAK3 and -5 were detectable with strong bands in only few prostate samples, while they were completely undetectable or only very faintly detectable in most samples (Fig 1B) . PAK2, -4, and -6 were detectable with almost constant intensity with one antibody, but only faintly detectable or undetectable with another antibody (Fig 1B) . Together, this suggests a constitutive expression at least of PAK1, and possibly of PAK2, -4, and -6, while expression of PAK3 and -5 may be inducible (Table 1) .
Similar to prostate tissues, PAK1 was the isoform, which was best detectable from all isoforms in Western blot analysis of WPMY-1 cells, using two different antibodies (Fig 1B) . In contrast, PAK6 was completely undetectable even using two different antibodies (Fig 1B) . Other isoforms were strongly detectable with one antibody, but only faintly detectable (PAK2, -4) or undetectable (PAK3) with another, while blurred bands for PAK5 appeared after detection with two different antibodies (Fig 1B) . Comparison with prostate tissues suggested that at least the expression of PAK1 and PAK5 in WPMY-1 cells may be higher than in prostate tissues ( Fig 1B, Table 1 ), what was confirmed by RT-PCR ( Fig 1A, Table 1 ).
In fluorescence stainings, sections of prostate tissues were double labeled for markers (calponin for smooth muscle cells, or pan-cytokeratin for epithelial cells of glands) and for those PAK isoforms, for which a constitutive expression may be assumed (PAK1, -2, -4, and -6) ( Table 1) . Isoform-specific PAK antibodies used for fluorescence labelings provided exclusively (PAK1, -2, -6) or prevailingly (PAK4) single bands with sizes of the expected molecular weights in Western blot analyses (S1 Fig). Stainings suggested that PAK1 may be the prevailing isoform with constitutive expression in smooth muscle cells, whereas PAK1, PAK2, PAK4, and PAK6 may be found in catecholaminergic nerves (Fig 2) .
BPH to different degree is considered typical for patients with prostate cancer, and is reflected by varying levels of prostate specific antigen (PSA) [38] . Hyperplasia in prostate samples was confirmed by varying content of PSA, calponin (smooth muscle marker) and panzytokeratin (epithelial marker, staining glandular cells) (Fig 1C) . In WPMY-1 cells, α 1A -adrenoceptors and the smooth muscle marker calponin, two important features of prostate smooth muscle cells were detectable, while pan-cytokeratin, a characteristic marker for epithelial, glandular cells, was lacking (Fig 1C) .
Inhibition of prostate smooth muscle contraction by PAK inhibitors
PAKs may be involved in smooth muscle contraction of the airways, cardiovascular system, and gastrointestinal tract [13] [14] [15] [16] [17] [18] [19] [20] [21] . This prompted us to examine effects of two different, small molecule PAK inhibitors, FRAX486 and IPA3 on contraction of human prostate smooth muscle. Selectivity of both inhibitors is highest for group I PAKs (i. e., PAK1-3), with IC 50 values below or around the low micromolar range in in vitro kinase assays [36, [39] [40] [41] . In organ bath experiments, contractions of prostate strips were induced frequency-or concentration-dependently by electric field stimulation (EFS), noradrenaline, the α 1 -adrenoceptor-selective agonist phenylephrine, endothelin-1, or endothelin-2 ( Figs 3 and 4) . EFS causes neuronal action potentials, leading to contraction by release of endogenous neurotransmitters [42, 43] . No inhibition of EFS-induced contractions was observed at lower inhibitor concentrations, i. e. using 10 μM of FRAX486 or 100 μM of IPA3 (Fig 3) . EFS-induced contractions were significantly inhibited by 30 μM of FRAX486 at all frequencies (Fig 4) . Similarly, EFS-induced contractions were inhibited by 300 μM of IPA3, which was significant at the highest frequency (32 Hz) (Fig 4) . Tensions after significant inhibition ranged around 50% of tensions in controls.
In a concentration of 10 μM, FRAX486 did not inhibit endothelin-induced contractions (Fig 3) . Noradrenaline-and phenylephrine-induced contractions were not altered by 30 μM of FRAX486 or 300 μM of IPA3 (Fig 4) . Endothelin-1-and -2-induced contractions were significantly inhibited by 30 μM of FRAX486 at each endothelin concentraction (Fig 4) . Endothelininduced tensions after significant inhibition were lower than 50% of tensions in controls.
Regression of actin organization by PAK inhibitors in WPMY-1 cells
It has been repeatedly reported that PAKs are important regulators of actin organization, so that they may be critical for actin-dependent functions including contraction or proliferation, among others [44] [45] [46] [47] . Therefore, we next examined effects of PAK inhibitors on actin organization cultured WPMY-1 cells. FRAX486 and IPA3 (both 1-10 μM, 24 h) caused concentration-dependent degeneration of actin filaments. Actin filaments in solvent-treated control cells were arranged to bundles, forming long and thin protrusions, with elongations from adjacent cells overlapping each other (Fig 5) . FRAX486 or IPA3 in concentrations of 1 μM caused partial loss of actin organization, including regressing degree of actin polymerization and degeneration of protrusions (Fig 5) . FRAX486 and IPA3 in concentrations of 5 or 10 μM caused complete breakdown of filament organization, resulting in a rounded cell shape without protrusions (Fig 5) . 
Cytotoxicity of PAK inhibitors in WPMY-1 cells
PAKs are critical for cellular survival, which has been mostly investigated in cancer cells [48] [49] [50] . Effects of PAK inhibitors on cellular survival may be crucial in vitro, but also for any application in vivo. Therefore, we assessed cytotoxicity of PAK inhibitors in WPMY-1 cells. Cytotoxicity of FRAX486 and IPA3 in WPMY-1 cells turned out to be concentration-and timedependent. Survival ranged between 55-82% after application of 1 μM FRAX486 for 24 h, or of 1 μM IPA3 for 24-72 h (Fig 6) . Higher concentrations and longer application gradually reduced survival: after application of 5 or 10 μM FRAX486 for 48-72 h, or of 10 μM IPA3 for 48-72 h, survival ranged between 1-5% (Fig 6) .
Inhibition of WPMY-1 cell proliferation by PAK inhibitors
PAKs promote proliferation in various cell types, including airway and vascular smooth muscle cells [22] [23] [24] [25] . As any effect on proliferation of prostate cells may be interesting for application in BPH, where hyperplastic growth induces symptoms, we examined effects of PAK inhibitors on proliferation of WPMY-1 cells. FRAX486 and IPA3 significantly reduced the relative proliferation rate in the remaining populations of WPMY-1 cells (Fig 7) . While 68% of solvent-treated (24 h) cells showed proliferation, proliferation rate after application of FRAX486 (1-10 μM, 24 h) ranged around 45%, or between 41-61% after application of IPA3 (1-10 μM, 24 h) (Fig 7) .
Agonist-induced PAK phosphorylation in WPMY-1 cells
Finally, we assessed whether PAKs may be activated by noradrenaline, endothelins, or dihydrotestosterone in WPMY-1 cells. Activation of group I PAKs includes phosphorylation at common positions, which may be investigated using phospho-specific antibodies [35] [36] [37] . Stimulation of WPMY-1 cells with endothelin-1 (3 μM) for 10 or 20 min increased the content of phosphorylated group I PAKs (i. e., PAK1-3), while the content of PAK1 and β-actin was similar in stimulated and control cells (Fig 8) . Similarly, increased phospho-PAK levels were observed after stimulation with dihydrotestosterone (100 μM) for 8 or 48 h, while the content of PAK1 and β-actin remained constant during stimulation (Fig 8) . Maximum agonist-induced phospho-PAK content was 198 ± 30% from controls after stimulation with endothelin-1 (20 min), or 297 ± 104% from controls after stimulation with dihydrotestosterone (48 h). Stimulation with endothelin-2 (3 μM) for 10 or 20 min, or with noradrenaline (100 μM) for 5 or 10 min did not change the content of phospho-PAK, PAK1, or β-actin (Fig 8) .
Discussion
Our findings show that it may be principally possible to target smooth muscle contraction and growth in the prostate at once, by single compounds. Both processes are critical for etiology and therapy of voiding symptoms in patients with BPH, but combination therapies are still required to reduce both at once [2] [3] [4] . Certainly, available medical options may improve the situation of many patients. Altogether, however, insufficient efficacy, disappointing responder rates, and high discontinuation rates provide clear limitations of current pharmacotherapy [2] [3] [4] [51] [52] [53] [54] [55] [56] . Although drugs concurrently addressing smooth muscle contraction and hyperplastic growth in the prostate may be attractive putative candidates for treatment of male LUTS, this possibility has been rarely considered. Here, we examined effects of PAK inhibitors on prostate smooth muscle contraction, and growth of stromal cells. Based on these observations in vitro, it may be expected that PAK inhibitors induce urodynamic effects in vivo. While available compounds for medical treatment of male LUTS either address (α 1 -adrenergic) contraction, or prostate size, PAK inhibitors were capable to affect adrenergic plus non-adrenergic contraction, and stromal cell growth at once in our study (Fig 9) . We are aware that any efficacy of PAK inhibitors for improvement of LUTS needs to be confirmed in vivo, and that applications may be limited by side-effects. FRAX486 has been developed recently, and its application for several days was tolerated in mice [40, 57] .
We used tissues from the periurethral zone, taken from prostates after radical prostatectomy for prostate cancer. We consider these samples as non-malignant and mostly hyperplastic for two reasons. First, samples were taken from the periurethral zone, while the great majority of tumors in prostate cancer is located to the peripheral zone [31, 32] . Consequently, macroscopical inspection of our radicals by pathologists before sampling never revealed tumors in the periurehtral zone. Secondly, most patients undergoing radical prostatectomy show BPH; it has been estimated that 80% of patients with prostate cancer show BPH [33, 34] . This is in line with the overall high prevalence of BPH, which increases with age. Thus, around 80% of men with an age of 80 years or older have BPH, while the average age of our patients undergoing radical prostatectomy ranges between 61-68 years [7, [58] [59] [60] . We confirmed BPH by detection Effects of PAK Inhibition in Benign Prostatic Hyperplasia of PSA in Western blot analysis: as the content of PSA increases with the degree of BPH, varying content of PSA in our samples reflects BPH with varying degree [38] .
Our findings suggest divergent PAK-dependent regulation of endothelin-and α 1 -adrenoceptor-mediated contractions. As FRAX486 and IPA3 inhibited EFS-induced, but not noradrenaline-or phenylephrine-induced contractions of prostate strips at least at higher concentrations, Effects of PAK Inhibition in Benign Prostatic Hyperplasia it may be assumed that PAKs might be critical for adrenergic neurotransmission in the hyperplastic human prostate, possibly by regulation of noradrenaline release. Double labeling of prostate sections with TH suggested expression of different PAK isoforms in catecholaminergic nerves of hyperplastic prostate tissues. In fact, expression of all PAK isoforms elsewhere in the nervous system is well known, and investigation of PAK regulation was often related to neuronal functions [10] . However, we cannot estimate which isoforms are involved in adrenergic neurotransmission in the prostate. This resembles the situation in many organs and cell types, where PAK functions are often poorly understood at isoform level [39, 61] .
As PAK1 may be the prevailing isoform in prostate smooth muscle cells, inhibition of PAK1 may be responsible for inhibition of endothelin-induced contractions by FRAX486. Obviously, PAK1 is capable to distinguish endothelin receptors from α 1 -adrenoceptors in smooth muscle cells, so that endothelin-but not α 1 -adrenoceptor-induced contraction is promoted by PAK1. Our phosphorylation experiments in WPMY-1 cells suggest that endothelin receptors, but not α 1 -adrenoceptors induce PAK activation. In fact, it has been previously suggested that PAKs may be involved in endothelin receptor-induced signaling [62] . This may explain selective effects of FRAX486 in our contraction experiments. We conclude that PAKs may promote prostate smooth muscle contraction by adrenergic neurotransmission, and by intracellular signaling through endothelin-1-, but not of α 1 -adrenoceptors. This model is summarized in Fig 9. Notably, endothelin-induced force generation was of similar range than α 1 -adrenergic contractions. Such contributions of non-adrenergic mediators to prostate smooth muscle tone may Effects of PAK Inhibition in Benign Prostatic Hyperplasia account for limitations of α 1 -blockers [2] . Consequently, it has been proposed that future therapies with higher efficacy than α 1 -blockers have to interfer with adrenergic and non-adrenergic contractions [63] .
To the best of our knowledge, our study is the first demonstrating inhibition of smooth muscle contraction by small molecule PAK inhibitors using any intact tissues. Nevertheless, it has been repeatedly proposed that PAKs are important regulators or mediators of smooth muscle contraction [13-16, 18-21, 64-68] . Such studies were based on application of antisense techniques in airway, vascular, or gastrointestinal tissues, or on investigation of cytoskeletal regulation in cell culture models. Different mechanisms have been suggested by which PAKs may promote smooth muscle contraction. It has been assumed that PAKs cooperate with Rac GTPases to promote smooth muscle contraction [64, 67, 69, 70] . In fact, Rac GTPases may be involved in smooth muscle contraction of the prostate [8] . However, PAK-mediated contraction in the prostate seems to be independent from Rac, because interactions between Rac and the putative Rac-binding domain of PAK were not observed in human prostate tissues [8] . Several models proposed PAK-mediated phosphorylation of myosin light chains for smooth muscle contraction [13, 68] . Other models of PAK function included the participation of PAKs in adhesome formation, following activation of the GTPase RhoA by contractile agonists and resulting in polymerization of actin [19, 21] . Actin polymerization is indispensable for smooth muscle contraction, and turned out to be susceptible to Rac inhibitors in WPMY-1 cells [8] . At present, we cannot explain, why we observed deorganization of actin filaments by PAK inhibitors, although α 1 -adrenoceptor-agonist contractions were not inhibited. However, this finding may be in line with a previous study, where IPA3 inhibited actin polymerization, without blunting thromboxane-induced contractions [71] . Together, this suggests that the function of PAK for smooth muscle contraction may differ between organs.
Our Western blot analyses suggested that PAK1 may be a prevailing group I PAK with constitutive expression in human prostate tissue. In fact, bands matching the molecular weight for this isoform were observed with most samples, although with varying intensity. Bands for PAK3 and PAK5 were observed in some, but not all samples, pointing to an expression pattern resembling an on-off principle. This may be explained by two different mechanisms. First, these PAK isoforms are generally not expressed (or at low levels only), but expression can be induced by (unkown) stimuli. Second, these PAK isoforms are generally expressed, but under certain circumstances (in response to unkown stimuli) they are degraded (= regulation at expression level). Regardless from the underlying mechanism, this shows that PAK3 and -5 may be inducible or subject of regulation. Therefore, it should be excluded that PAK3 or -5 account for effects of FRAX486 or IPA3 in prostate tissues.
In WPMY-1 cells, effects of FRAX486 on actin organization, survival, and proliferation occurred already at concentrations of 1-5 μM. In these concentrations, full inhibition of PAK1-3 may be expected, while PAK4 may be inhibited only partially [40] . In vitro kinase assays using pure enzymes revealed IC 50 values for FRAX486 between 10-100 nM for PAK1-3, while the IC 50 of 779 nM for PAK4 was just below the micromolar range [40] . It has to be kept in mind, that any IC 50 in in vitro kinase assays may be considerably lower than EC 50 values in vivo, or in cultured cells and intact tissues. For FRAX486, an EC 50 value of 500 nM has been reported from cells (5-50fold higher than IC 50 ), so that full effects ("EC 100 ") may be expected in the micromolar range [57] . It appears naturally, that effective concentrations in tissues may be again higher than in cell culture, due to connective tissue, extracellular matrix components, or small interstitial spaces, which may limit accessability of inhibitors to targets in tissues but not in cell culture. At least for FRAX486, increasing the concentrations from 1 μM up to 10 μM did not further increase the effects in WPMY-1 cells, what may suggest that there are no effects from unspecific kinase inhibition (i. e., from non-p21-activated kinases) at higher concentrations. Similarly, we assume that effects of IPA3 in WPMY-1 cells were caused by inhibition of group I PAKs (i. e., PAK1-3), as IPA3 is specific for PAK1-3 within a low micromolar range, but does not inhibit more distantly related PAKs (PAK4-6) or other kinases [36, 39, 41] . Finally, our observation that effective concentrations in prostate tissues were higher than in WPMY-1 cells (i. e., 10 μM FRAX486 were effective in cells, but not in tissues) may be explained by different content of PAK1, which may be higher in WPMY-1 cells than in prostate tissues.
Our findings with PAK inhibitors in WPMY-1 cells are in line with previous observations. Thus, a critical role of PAKs for actin organization, including polymerization and its organization to filaments, as well as a role for actin-dependent functions such as migration, morphology, proliferation, or contraction was observed in various cell types [35, [44] [45] [46] [47] 72] . Deorganization of actin filaments, going along with depolymerization, shortening of filaments, and alterations in morphology can be seen in our phalloidin stainings of WPMY-1 cells. Similar to our observation that cell cycle in prostate stromal cells is PAK-dependent, PAKs were previously found to promote proliferation in airway and vascular smooth muscle cells [22] [23] [24] [25] . In the cardiovascular system, PAK1 participates in vascular remodeling, so that an analog role in hyperplastic prostate growth appears now possible [22, 24, 73] . Due to their shared contributions to etiology of voiding symptoms, links between smooth muscle contraction and hyperplastic growth in the prostate have been assumed [2, 5] . Notably, our findings suggest that PAKs may be activated by dihydrostestosterone, which is critical in prostate growth and hyperplasia. This may support the idea, that PAKs are involved in hyperplastic growth besides their role for contraction. Obviously, hyperplastic growth and contraction in BPH are no separate phenomenons, but synchronized and connected with each other by shared molecular mediators, including PAKs.
Conclusions
Here, we show that control of smooth muscle contraction and stromal growth in the human prostate may be both susceptible to small molecule PAK inhibitors. PAK inhibitors inhibit prostate smooth muscle contraction, and growth of prostate cells, which may both contribute to voiding symptoms. Our findings show that simultaneous targeting of contraction and growth in the prostate by single compounds is principally possible.
Supporting Information S1 Fig. Complete lanes from Western blot analyses of human prostate tissues (A) and WPMY-1 cells (B) using two different isoform-specific PAK antibodies for each isoform. In (A) and (B), upper panels show analyses using polyclonal rabbit or goat antibodies, while monoclonal mouse antibodies were applied in analyses of lower panels. Shown is the total range of membranes being exposed to detection. Numbers left to blots indicate molecular weights (kDa), obtained by a commercially available prestained marker, with the 75 kDa band being stressed and aligned in each line. Arrows indicate bands matching the expected molecular weight of PAK isoforms; if antibodies did not yield bands with expected sizes, arrows indicate the regions where correct bands should be expected. (TIF) University, Munich) and his coworkers Dr. V. Mai and Dr. C. Faber for asservation of tissue samples from prostates. This study was supported by grants from the Deutsche Forschungsgemeinschaft (grants HE 5825/2-1, and GR 3333/2-1).
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